Evidence map›Paper›PMID 26979993›Full record

ReviewBrain research2016

Immunoprecipitation and mass spectrometry defines an extensive RBM45 protein-protein interaction network.

Yang Li, Mahlon Collins, Jiyan An, Rachel Geiser, Tony Tegeler, Kristine Tsantilas, Krystine Garcia, Patrick Pirrotte, Robert Bowser

Open access · hybridAbstract readReview
In one paragraph

Review in Brain research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. RBM45 Preferential Binding to mThe journal of physical chemistry. B · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Syndecan-4 Mediates the Cellular Entry of Adeno-Associated Virus 9.International journal of molecular sciences · 2023
    Article
  7. Article
  8. RBM45 is an mCell reports · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yang LiDivisions of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph׳s Hospital and Medical Center, Phoenix, AZ 85013, USA.
Mahlon CollinsDivisions of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph׳s Hospital and Medical Center, Phoenix, AZ 85013, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Jiyan AnDivisions of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph׳s Hospital and Medical Center, Phoenix, AZ 85013, USA.
Rachel GeiserDivisions of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph׳s Hospital and Medical Center, Phoenix, AZ 85013, USA.
Tony TegelerCenter for Proteomics, TGen (Translational Genomics Research Institute), Phoenix, AZ 85004, USA.
Kristine TsantilasCenter for Proteomics, TGen (Translational Genomics Research Institute), Phoenix, AZ 85004, USA.
Krystine GarciaCenter for Proteomics, TGen (Translational Genomics Research Institute), Phoenix, AZ 85004, USA.
Patrick PirrotteCenter for Proteomics, TGen (Translational Genomics Research Institute), Phoenix, AZ 85004, USA.
Robert BowserDivisions of Neurology and Neurobiology, Barrow Neurological Institute, St. Joseph׳s Hospital and Medical Center, Phoenix, AZ 85013, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA. Electronic address: Robert.Bowser@DignityHealth.org.
Barrow Neurological Institute · USTranslational Genomics Research Institute · US

Funding

Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)R01NS061867 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOWSER, ROBERT P · 2009 to 2013
$1.6M
Multi-Center Validation of Biomarkers for Motor Neuron DiseaseRC1NS068179 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOWSER, ROBERT P, CUDKOWICZ, MERIT E · 2009 to 2010
$977k
Peptide and Protein Biomarkers for Amyotrophic Lateral Sclerosis (ALS)R56NS061867 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI BOWSER, ROBERT P · 2014 to 2014
$687k
The Functional Role of RBM45 in Gene Expression and NeurodegenerationF31NS080614 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI COLLINS, MAHLON · 2012 to 2014
$119k
NINDS NIH HHS F31 NS080614NINDS NIH HHS R01 NS061867NINDS NIH HHS R56 NS061867NINDS NIH HHS RC1 NS068179
6 · The paper itself

Abstract

The pathological accumulation of RNA-binding proteins (RBPs) within inclusion bodies is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RBP aggregation results in both toxic gain and loss of normal function. Determining the protein binding partners and normal functions of disease-associated RBPs is necessary to fully understand molecular mechanisms of RBPs in disease. Herein, we characterized the protein-protein interactions (PPIs) of RBM45, a RBP that localizes to inclusions in ALS/FTLD. Using immunoprecipitation coupled to mass spectrometry (IP-MS), we identified 132 proteins that specifically interact with RBM45 within HEK293 cells. Select PPIs were validated by immunoblot and immunocytochemistry, demonstrating that RBM45 associates with a number of other RBPs primarily via RNA-dependent interactions in the nucleus. Analysis of the biological processes and pathways associated with RBM45-interacting proteins indicates enrichment for nuclear RNA processing/splicing via association with hnRNP proteins and cytoplasmic RNA translation via eiF2 and eiF4 pathways. Moreover, several other ALS-linked RBPs, including TDP-43, FUS, Matrin-3, and hnRNP-A1, interact with RBM45, consistent with prior observations of these proteins within intracellular inclusions in ALS/FTLD. Taken together, our results define a PPI network for RBM45, suggest novel functions for this protein, and provide new insights into the contributions of RBM45 to neurodegeneration in ALS/FTLD. This article is part of a Special Issue entitled SI:RNA Metabolism in Disease.

Indexed as

Amyotrophic Lateral SclerosisEukaryotic Initiation Factor-2Frontotemporal Lobar DegenerationHEK293 CellsHumansImmunoprecipitationInclusion BodiesMass SpectrometryNerve Tissue ProteinsPeptide Initiation FactorsProtein Interaction MapsRNA-Binding ProteinsRNA SplicingSignal TransductioneIF-4Eukaryotic Initiation Factor-2Nerve Tissue ProteinsPeptide Initiation FactorsRBM45 protein, humanRNA-Binding ProteinsALSImmunoprecipitationMass spectrometryProtein–protein interactionRBM45

Identifiers

PMID26979993
PMCPMC5152586
OpenAlexW2294908122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.